Naive treatment of patients w/ locally advanced or metastatic NSCLC w/ activating mutations of the EGFR TK, or those who have previously received chemotherapy or who are not suitable for chemotherapy.
View Gefitero overdosage for action to be taken in the event of an overdose.
Administration
May be taken with or without food: Tab may be dispersed in ½ glass of non-carbonated drinking water. No other liqd should be used. Drop the tab in water & w/o crushing it, stir until dispersed (approx 20 min). Drink the liqd immediately. Rinse the glass w/ another ½ glass of water & drink. Dispersed liqd may also be administered via a nasogastric tube.
EGFR mutation assessment of the tumour tissue is attempted for all patients. Interstitial lung disease. Patients w/ concurrent idiopathic pulmonary fibrosis/interstitial pneumonia/pneumoconiosis/radiation pneumonia/drug-induced pneumonia. Discontinue treatment if ILD is confirmed; severe changes in liver function. Liver function abnormalities. Periodic LFTs is recommended. Co-administration w/ CYP3A4 inducers (eg, phenytoin, carbamazepine, rifampicin, barbiturates or St. John's wort). Monitor patients taking warfarin for changes in prothrombin time or INR. Advise patient to seek immediate medical advice in the event of developing severe or persistent diarrhea, nausea, vomiting or anorexia. Keratitis should be referred promptly to ophth specialist & treatment interrupted if confirmed. May exacerbate the neutropenic effect of Vinorelbine. GI perforation. May impair ability to drive or use machinery due to asthenia. Women of childbearing potential must avoid becoming pregnant. Pregnancy & lactation. Not recommended in childn & adolescents.
Sign Out
